The rise of biologics and complex therapeutics is driving innovation in large-volume subcutaneous (LVSC) drug delivery. In a recent article published in ONdrugDelivery, Ypsomed experts Dr. Andreas Schneider and Dr. Jakob Lange discuss the opportunities and challenges of transitioning high-dose therapies from intravenous (IV) to subcutaneous (SC) administration.
Expanding the possibilities of LVSC delivery
The article highlights findings from the study “Navigating Large-Volume Subcutaneous Injections of Biopharmaceuticals: A Systematic Review of Clinical Pipelines and Approved Products” (Green et al., 2024), which provides an overview of clinical-stage and approved LVSC biopharmaceuticals, offering insights into dose-volume trends, therapeutic categories, and emerging delivery challenges.
Ypsomed’s LVSC delivery portfolio addresses many of these challenges with solutions such as the YpsoMate 2.25 with an 8 mm needle configuration, the YpsoMate 2.25 Pro and YpsoMate 5.5, which support SC injections for mid to large-sized volumes while managing high-viscosity formulations. For even larger doses, the YpsoDose patch injector provides a fully industrialised, patient-centric solution for up to 10 mL of drug delivery.
With these platforms, Ypsomed addresses key challenges in LVSC delivery, including reducing injection times, improving patient comfort, lowering healthcare and logistical costs and enabling self-administration of high-dose therapies.
For more insights into the future of LVSC biopharmaceuticals and Ypsomed’s role in driving this transition, we invite you to read the full article in ONdrugDelivery.
Stay tuned, stay informed
Subscribe to the Ypsomed Blog and join our journey to simpler and easier selfcare.
